According tomedia reports, a small study reported that patients with new coronary pneumonia with the over-the-counter heartburn drug “famotidine” treatment, symptoms have improved significantly. The study was very small, with only 10 participants, but the results were promising. The study was published in the journal Gut.
Those who took part in the study began taking “high doses” of famotitin, an over-the-counter ingredient in Pepcid, a brand of anti-ulcer drugs. Notably, all 10 volunteers reported that their symptoms improved within 48 hours, and many noted a significant improvement within a day of starting medication.
The parameters of the study are described as follows:
Ten COVID-19 patients were identified with high doses of oral mobutytin. The most common method of famotitinis is 80mg, three times a day (n-6), with a median of 11 days (range: 5-21 days). Famotitina is well tolerated. All patients said that the symptoms associated with the disease improved significantly after the use of famotitin. The syndrome score improved significantly within 24 hours of the beginning of the famotitin, and increased peripheral oxygen saturation (n-2) and activity recorded by the device (n-1).
“The results of this series of cases show that high-dose oral mobutytin is well tolerated in non-hospitalized COVID-19 patients and is associated with improved patient reporting outcomes,” the study said. “
Common symptoms of new coronavirus infection are reported, including coughing, shortness of breath, fatigue, headache and anorexia, and improved “general discomfort.”
But it’s worth noting that this is an incredibly small sample size. The results of the study were not highly valued given that the results of the study were not well collected by 10 people who had passed the test alone, and given that it had not been tested in any way by a placebo-controlled or blind-law.
Nevertheless, it is noteworthy that each participant reported positively improving their symptoms after taking heartburn medication. As the researchers point out, the findings require larger control studies to determine whether the drug can actually be used to aid the treatment of COVID-19 patients.